Sartorius Stedim Biotech (WBO:DIM) COGS-to-Revenue : 0.52 (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Sartorius Stedim Biotech COGS-to-Revenue?

Sartorius Stedim Biotech's Cost of Goods Sold for the three months ended in Mar. 2025 was €388 Mil. Its Revenue for the three months ended in Mar. 2025 was €745 Mil.

Sartorius Stedim Biotech's COGS to Revenue for the three months ended in Mar. 2025 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sartorius Stedim Biotech's Gross Margin % for the three months ended in Mar. 2025 was 47.85%.

Sartorius Stedim Biotech COGS-to-Revenue Historical Data

The historical data trend for Sartorius Stedim Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech COGS-to-Revenue Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.47

0.46

0.48

0.56

0.57

Sartorius Stedim Biotech Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.54	0.57	0.58	0.58	0.52

Sartorius Stedim Biotech COGS-to-Revenue Calculation

Sartorius Stedim Biotech's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1573.3	/	2780
	=	0.57

Sartorius Stedim Biotech's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	388.3	/	744.6
	=	0.52

Sartorius Stedim Biotech (WBO:DIM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sartorius Stedim Biotech's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	388.3 / 744.6
	=	47.85 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Sartorius Stedim Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (WBO:DIM) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

SRTOY:USA SDMHF:USA DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.